Menu Back to DIA-Pharmacovigilance-and-Risk-Management-Strategies-2017

Program Committee

  • Stella  Blackburn, MD, MA, MSc, FFPM, FISPE, FRCP
    Stella Blackburn, MD, MA, MSc, FFPM, FISPE, FRCP Vice President, Global Head of Early Access and Risk Management
    IQVIA, United Kingdom
  • James  Wabby, MHS
    James Wabby, MHS Executive Director, Regulatory Affairs, Devices and Combination Products
    Allergan, United States
  • Mariette  Boerstoel-Streefland, MD, MBA, MS
    Mariette Boerstoel-Streefland, MD, MBA, MS Senior Vice President, Global Drug Safety
    Alexion, United States
  • E. Stewart  Geary, MD
    E. Stewart Geary, MD Senior VP, Chief Medical Officer, Director, Corporate Medical Affairs HQ
    Eisai Co., Ltd., Japan
  • Elizabeth E. Garrard, PharmD
    Elizabeth E. Garrard, PharmD Executive Vice President, Global Safety Operations
    Clinipace Worldwide, United States
  • Lisa Melanie Harinstein, PharmD
    Lisa Melanie Harinstein, PharmD Safety Evaluator, Division of Pharmacovigilance-I, Office of Surveillance , CDER
    FDA, United States
  • Stephen  Knowles, MD, MRCP
    Stephen Knowles, MD, MRCP President, Drug Safety, and Pharmacovigilance
    Halozyme Therapeutics, United States
  • Robert L. Levin, MD
    Robert L. Levin, MD Lead Medical Officer for Pharmacovigilance Strategy
    FDA, United States
  • Michael  Richardson, MD, FFPM
    Michael Richardson, MD, FFPM International GPV&E and EU QPPV
    Bristol-Myers Squibb, United Kingdom
  • Annette  Stemhagen, DrPH, FISPE
    Annette Stemhagen, DrPH, FISPE Senior Vice President, Safety, Epidemiology, Registries, and Risk Management
    UBC, United States
  • Mick  Foy
    Mick Foy Head of Pharmacovigilance Strategy
    Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom
Load More

Digital Learning Catalog

DIA Learning: eLearning Soultions